<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cancer Vaccines on FinanClub</title>
    <link>https://finan.club/tags/cancer-vaccines/</link>
    <description>Recent content in Cancer Vaccines on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 27 Feb 2024 09:04:54 +0000</lastBuildDate><atom:link href="https://finan.club/tags/cancer-vaccines/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Tue, 27 Feb 2024 09:04:54 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:142
Chances: Completion of enrollment for safety portions of a clinical trial is a positive indicator of progress for the company Findings from Patient-Reported Outcomes (PROs) and positive interim results from the QUILT 3.032 study showcase the potential of ImmunityBio’s therapies Acceptance for review of the Biologics License Application (BLA) for N-803 by the FDA demonstrates a significant milestone for the company Risks: The success of the clinical trials and the FDA review are crucial for the company’s future prospects, and any setbacks in these processes could impact the stock performance Competitive landscape and regulatory environment for immunotherapy companies may pose challenges Score:142 chances characters count - risks characters count = 142</description>
    </item>
    
    <item>
      <title>MRNA</title>
      <link>https://finan.club/us/mrna/</link>
      <pubDate>Wed, 17 Jan 2024 09:04:41 +0000</pubDate>
      
      <guid>https://finan.club/us/mrna/</guid>
      <description>score:-55
Chances: Moderna&amp;rsquo;s product pipeline includes a wide range of modalities, such as prophylactic vaccines, cancer vaccines, and localized regenerative therapeutics, providing opportunities for significant future growth. The company&amp;rsquo;s focus on intratumoral immuno-oncology and systemic intracellular therapeutics reflects a strong commitment to addressing complex medical challenges with innovative solutions.</description>
    </item>
    
  </channel>
</rss>
